Login to Your Account

LPath Inks $500M+ Deal with Pfizer for Cancer, Eye Drugs

By Trista Morrison

Tuesday, December 21, 2010
LPath Inc. saw its stock jump 38.7 percent Monday after unveiling a potentially lucrative option deal with Pfizer Inc. covering lead antibodies iSONEP for ophthalmology and ASONEP for cancer.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription